ArriVent BioPharma (AVBP) Non-Current Assets (2023 - 2026)

ArriVent BioPharma has disclosed Non-Current Assets across 4 years of filings, most recently posting $595000.0 for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $595000.0, down 98.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.6 million (down 67.37% YoY), and the FY2025 annual result was $272000.0, down 99.43% from the prior year.
• Non-Current Assets came in at $595000.0 for Q1 2026 at ArriVent BioPharma, up from $272000.0 in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $48.0 million in Q4 2024 to a low of $272000.0 in Q4 2025.
• The 4-year median for Non-Current Assets is $1.9 million (2023), against an average of $10.7 million.
• Peak annual rise in Non-Current Assets reached 8198.88% in 2025, while the deepest fall reached 99.43% in 2025.
• ArriVent BioPharma's Non-Current Assets stood at $3.1 million in 2023, then jumped by 1432.36% to $48.0 million in 2024, then slumped by 99.43% to $272000.0 in 2025, then surged by 118.75% to $595000.0 in 2026.
• The last three Non-Current Assets figures came in at $595000.0 (Q1 2026), $272000.0 (Q4 2025), and $5.3 million (Q3 2025), per Business Quant data.